 |
| Apollo's human expressed protein is in demand |
Apollo's hcx proteins | Apollo is seeing strong growth in customers of its human expressed proteins, with a massive 680 per cent increase in the last quarter.
Of even greater importance is the fact that – of Apollo’s first-time customers, 91 per cent are returning to do repeat business, according to Leanne Daly, President of Sales and Marketing. “Our corporate clientele now includes global pharmaceutical companies GlaxoSmithKline, Amgen, Nova Nordisk, Novartis and Receptor Biologics – their custom is an endorsement of the quality and uniqueness of our product range,” she said.
Apollo’s top corporate customers for its human-expressed (hcx™) proteins include US and European firms as well as the Australian Red Cross which uses hcx™ proteins in its diagnostic testing.
Amgen
Australia Red Cross Blood Service
Avidia Inc
Cell Signal Technologies
Chemie Brunscwig AG
GlaxoSmithKline
Novartis Pharma AG
Novo Nordisk
Receptor Biologix
Xoma (US) LLC |
USA
Australia
USA
USA
Europe
USA
Europe
Europe
USA
USA
|
Leanne Daly says current sales trend are positive, making the company one of only a handful of Australia’s 400+ biotechnology companies with products on the market and an expanding client base. “This compares to more biotechs that license out their IP to other companies, thereby losing access to real profits,” she said.
“The global market for human proteins as research proteins is currently estimated at US$500 million, but most human proteins are currently synthesized in transgenic rodent or Escherichia coli bacterial cultures – making Apollo a likely candidate for a large share of this growing market.”
Bacteria cannot accurately replicate the results of post-translational modification processes unique to human cells, such as glycosylation, that fine-tune the structure and function of proteins to the host organism's requirements.
Research has shown that post-translational modifications can be critical to the function of protein therapeutics - incorrectly glycosylated proteins, for example, may provoke an immune response against a therapeutic protein.
Daly said a wide range of post-translational modifications influence cell growth, embryonic development, tissue repair, blood vessel growth and hormonal signalling between cells.
Apollo’s human-expressed proteins will have advantages over rodent and bacterially expressed proteins. They are used for a variety of purposes including high level detection for drug development, and inflammation, metabolic and cancer therapeutic research. As well, Apollo's proteins are increasingly being used in the stem cell activation area, where the use of human expressed protein is important for most optimum performance of the stem cell.
If used solely in research, proteins do not require regulatory consent from the US Food and Drug Administration or Australia's Therapeutic Goods Administration. However, Apollo's human proteins are produced in accordance with strict international guidelines.
Apollo dominates the market with a substantial product range. The company's hcx™ protein library provides multiple commercialization options. The unique protein library will be the basis for creating therapeutic products that will allow Apollo to enter the biopharmaceutical field with superior products, and to create novel therapies for a number of diseases. The size of the therapeutic protein market is estimated at US $57 billion.
|
|
|
| click to subscribe |
|
 |
| www.apollolifesciences.com |
